Personalized immune cells for highly sensitized kidney patients
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and on the kidney transplant waiting list.
- You are highly sensitized, meaning your immune system reacts to many potential donors (cPRA score 90% or higher).
- Your transplant team believes you have a good chance of receiving a kidney in the next 12 months.
- You have veins that can handle a blood-collection procedure called leukapheresis.
- You do not have active infections like tuberculosis, HIV, hepatitis B or C, or certain other viruses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a personalized approach (including tacrolimus medication planning and monitoring) to better understand how a kidney transplant is doing. It may help your transplant team tailor care to your kidney function over time.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.